PTC Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration
PTC Therapeutics, Inc. (PTCT) had Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration of $62.30 million as of 2021-12-31, per its 10-K filed 2022-02-22.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Alternative
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration · last filed 2022-02-22
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $62.30M.
- 2020-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $62.30M.
- 2019-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $62.30M.
- 2018-12-31: Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration $62.30M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration |
|---|---|
| 2021-12-31 | $62.30M 10-K · filed 2022-02-22 |
| 2020-12-31 | $62.30M 10-K · filed 2021-02-25 |
| 2019-12-31 | $62.30M 10-K · filed 2020-03-02 |
| 2018-12-31 | $62.30M 10-K · filed 2019-03-01 |
| 2017-12-31 | $62.30M 10-K · filed 2018-03-06 |
| 2016-12-31 | $62.30M 10-K · filed 2017-03-16 |
| 2015-12-31 | $62.30M 10-K · filed 2016-02-29 |
| 2014-12-31 | $62.30M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |